quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·86d
PRRelease
Quoin Pharmaceuticals Ltd. logo

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

QNRX· Quoin Pharmaceuticals Ltd.
Health Care
Original source

Companies

  • QNRX
    Quoin Pharmaceuticals Ltd.
    Health Care

Related

  • INSIDER23d
    SEC Form 4 filed by Stonepine Capital Management, Llc
  • SEC28d
    SEC Form 10-K filed by Quoin Pharmaceuticals Ltd.
  • SEC28d
    Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR28d
    Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
  • PR29d
    Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
  • PR35d
    Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
  • SEC43d
    SEC Form 8-K filed by Quoin Pharmaceuticals Ltd.
  • PR43d
    Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022